<DOC>
	<DOCNO>NCT01963143</DOCNO>
	<brief_summary>The primary objective demonstrate bioequivalence Gammaplex® 10 intravenous immunoglobulin ( IGIV ) Gammaplex® 5 % IGIV respect area curve within 28-day dose interval ( AUC0-28 ) cohort adult subject . The secondary objective demonstrate bioequivalence Gammaplex® 10 IGIV Gammaplex® 5 % IGIV respect area curve within 21-day dose interval ( AUC0-21 ) adult subject ; ass pharmacokinetics Gammaplex 10 IGIV Gammaplex 5 % IGIV include Immunoglobulin G ( IgG ) trough level investigate safety tolerability Gammaplex 10 IGIV Gammaplex 5 % IGIV adult subject ; ass pharmacokinetics Gammaplex 10 IGIV include IgG trough level investigate safety tolerability Gammaplex 10 IGIV pediatric subject .</brief_summary>
	<brief_title>Bioequivalence Study Evaluate Pharmacokinetics , Safety , Tolerability Gammaplex® 10 Gammaplex® 5 % Primary Immunodeficiency Diseases</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Agammaglobulinemia</mesh_term>
	<mesh_term>Common Variable Immunodeficiency</mesh_term>
	<mesh_term>Hyper-IgM Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Hyper-IgM Immunodeficiency Syndrome , Type 1</mesh_term>
	<mesh_term>Genetic Diseases , X-Linked</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Inclusion criterion : 1 . Adult cohort : The subject age 16 55 year inclusive , either sex , belong ethnic group . Pediatric cohort : The subject age 2 15 year inclusive , either sex , weigh least 10 kg , belong ethnic group . 2 . The subject primary immunodeficiency disease , e.g . common variable immunodeficiency , X link autosomal form agammaglobulinemia , hyper IgM ( Immunoglobulin M ) syndrome . Isolated deficiency single IgG subclass specific antibody without hypogammaglobulinemia per se , qualify inclusion . 3 . The subject currently receive license IGIV ( investigational stage III , IIIb IGIV ) dose change ± 50 % mean dose least three month study entry 300 800 mg/kg/infusion . The infusion interval must either every 21 every 28 day . 4 . The subject must trough level ≥ 6 g/L ( 600 mg/dL ) . At least one document trough level must available three month Screening . 5 . The subject must documentation last three consecutive routine IGIV infusion follow , first infusion study : dose IGIV , treatment interval , trade name ( identity ) IGIV treatment . 6 . Female subject childbearing potential must negative result HCG ( human chorionic gonadotropin ) base pregnancy test Screening . 7 . Females become sexually active must practice contraception use method proven reliability study duration . 8 . The subject willing comply aspect protocol duration study . 9 . The subject sign informed consent form assent form ( applicable ) . Exclusion criterion : 1 . The subject history severe anaphylactic reaction blood blood derive product . 2 . The subject selective IgA deficiency , history reaction product contain IgA ( Immunoglobulin A ) , history antibody IgA . 3 . The subject cellular innate impair immunity ( i.e . subject humoral impaired immunity may include ) . 4 . The subject evidence active infection time enrolment . 5 . The subject previously complete withdrawn study . 6 . The subject currently receive , receive , investigational agent IGIV within prior three month . 7 . The subject pregnant nursing . 8 . The subject positive result follow Screening : Serological test HIV 1 2 , HCV , HBsAg NAT ( Nucleic acid amplification technique ) HCV NAT HIV 9 . The subject level &gt; 2.5 time upper limit normal , defined central laboratory , follow Screening : Alanine amino transaminase Aspartate amino transaminase 10 . The subject severe renal impairment ( define serum creatinine great two time upper limit normal blood urea nitrogen great 2.5 time upper limit normal range laboratory analysis ) ; subject dialysis ; subject history acute renal failure . 11 . The subject know abuse alcohol , opiates , psychotropic agent , chemical drug , do within past 12 month . 12 . The subject history deep vein thrombosis thrombotic complication IGIV therapy . 13 . The subject suffers acute chronic* medical condition ( e.g . renal disease predispose condition renal disease , coronary artery disease , protein lose state ) Investigator feel may interfere conduct study . 14 . The subject acquire immunodeficiency condition chronic* lymphocytic leukemia , lymphoma , multiple myeloma , chronic recurrent neutropenia ( absolute neutrophil count &lt; 1 × 109/L ) . 15 . The subject receiving follow medication : Steroids ( long term daily , ≥ 0.15 mg prednisone equivalent/kg/day ) . Requirement short intermittent course steroid would exclude subject . Immunosuppressive drug Immunomodulatory drug 16 . The subject uncontrolled arterial hypertension ( systolic blood pressure &gt; 160 mm Hg and/or diastolic blood pressure &gt; 100 mm Hg ) . 17 . The subject anemia ( hemoglobin &lt; 10 g/dL ) Screening . 18 . The subject know intolerant component Gammaplex , sorbitol ( i.e . hereditary intolerance fructose ) glycine . Chronic condition would per Investigator 's opinion however study guidance condition present least 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>